Deltex Medical Group PLC Finance Director Appointed (0242U)
20 November 2019 - 6:30PM
UK Regulatory
TIDMDEMG
RNS Number : 0242U
Deltex Medical Group PLC
20 November 2019
20 November, 2019
Deltex Medical Group plc
("Deltex Medical", "DEMG" or "the Group")
Finance Director Appointed
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), is pleased to announce the
appointment of David Moorhouse as Group Finance Director with
immediate effect.
David brings to DEMG a wide breadth of financial experience, as
well as a very good understanding of the business having previously
been Finance Director at the company from 1996-2001. He has been
overseeing the finance function at DEMG on an interim basis since 7
October 2019. Most recently, David was Head of Finance and
Administration of the International Coffee Organization from 2004
to 2017. Prior to this, he served in a number of roles including in
corporate finance at European Banking Company, and as a Managing
Director at an executive search firm, Russell Reynolds Associates
Inc. in London and Frankfurt.
After graduating in Modern Languages from Queens' College,
Cambridge in 1974, David started work at Kleinwort Benson Ltd, a
merchant bank and subsequently qualified as a Chartered Accountant
with Price Waterhouse & Co.
Nigel Keen, Chairman of Deltex Medical Group plc, commented:
"I am delighted that David has agreed to re-join the Board of
DEMG. There is no doubt that his previous knowledge of the company
along with his experience across a multitude of sectors will be
invaluable to DEMG as we continue to deliver on our strategy."
The following information in relation to the appointment of Mr
David Philip Moorhouse (aged 67) is disclosed in accordance with
Schedule 2(g) of the AIM Rules for Companies.
Current directorships Past directorships held within
the last five years
None. None.
-------------------------------
Mr Moorhouse has an interest in 13,405 ordinary shares of 1
pence each ("Ordinary Shares") in the capital of Deltex Medical and
does not hold any options over shares in the capital of the
company.
There is no further information to be disclosed in relation to
Mr Moorhouse's appointment pursuant to AIM Rule 17 or Schedule 2(g)
of the AIM rules for companies.
For further information, please contact:
Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman investorinfo@deltexmedical.com
Andy Mears, Chief Executive
David Moorhouse, Finance Director
Nominated Adviser & Joint Broker
Arden Partners plc 020 7614 5900
Ciaran Walsh
Dan Gee-Summons
Joint Broker
Turner Pope Investments (TPI)
Ltd 0203 657 0050
Andy Thacker info@turnerpope.com
Zoe Alexander
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary oesophageal Doppler
monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity
in the central circulation in real time. Minimally invasive, easy
to set-up and quick to focus, the technology generates a
low-frequency ultrasound signal which is highly sensitive to
changes in blood flow and measures such changes in 'real time'.
Deltex Medical is the only company in the enhanced haemodynamic
space to have built a robust and credible evidence base
demonstrating both the clinical and economic benefits of its core
technology, TrueVue Doppler. This technology has been proven in a
wide range of clinical trials to reduce complications suffered by
patients after surgery and consequently save hospitals the costs of
treating those complications.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor
platform now provides clinicians with two further advanced
haemodynamic monitoring technologies. TrueVue Impedance is an
entirely non-invasive monitoring technology which transmits low
magnitude, high frequency electrical signals through the thorax and
measures the changes to this signal when the heart pumps blood.
TrueVue PressureWave uses the peripheral blood pressure signal
analysis to give doctors information on changes in the circulation
and is particularly suited to monitoring lower risk or
haemodynamically stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as an
important part of the anaesthesia protocol for surgical patients.
Consequently, the Group's focus is on maximising value from the
opportunities presented, as enhanced haemodynamic management is
adopted into routine clinical practice around the world. The Group
aims to provide clinicians with a single platform - a 'haemodynamic
workstation' - which offers them a range of technologies from
simple to sophisticated to be deployed according to the patient's
condition as well as the skill and expertise of the user. Doing
this will enable the Group to partner healthcare providers to
support modern haemodynamic management across the whole
hospital.
The Group is currently in the implementation phase of achieving
this goal in a number of territories worldwide, operating directly
in the UK and the USA, and through distribution arrangements in
approximately 40 other countries.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RDNLIFFDLLLIFIA
(END) Dow Jones Newswires
November 20, 2019 02:30 ET (07:30 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024